1 week Ago By [email protected] (MENAFN)
The report delivers an in-depth understanding of kidney transplant rejection, historical and forecasted epidemiology, as well as the kidney transplant rejection market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. The kidney transplant rejection market report provides current treatment practices, emerging drugs, market share of individual therapies, and current and forecasted 7 Major Markets (7MM) kidney transplant rejection market size from 2020 to 2034. The report also covers kidney transplant rejection treatment practices and unmet medical needs to curate the best opportunities and assess the market's potential.
In 2023, there were approximately 44 thousand incident cases of kidney transplants in the 7MM. Of these, the United States accounted for 62% of the cases, while EU4 and the UK accounted for nearly 34% and Japan represented 4% of the cases, respectively. Kidney Transplant Rejection Epidemiology As the market is derived using a patient-based model, the kidney transplant rejection epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by total incident cases of kidney transplants, total living cases of kidney transplants and type-specific cases of kidney transplant rejection in the 7MM covering the United States, EU4 countries (Germany, France, Italy, and Spain) and the United Kingdom, and Japan from 2020 to 2034.
Kidney Transplant Rejection Drug Chapters The drug chapter segment of the kidney transplant rejection report encloses a detailed analysis of kidney transplant rejection prophylaxis marketed drugs and mid to late-stage (Phase III and Phase II) pipeline drugs. It also helps understand the kidney transplant rejection clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases. Marketed Kidney Transplant Rejection - Prophylaxis Drugs Emerging Drugs Market Outlook Kidney transplant rejection is a major concern for recipients, as it can severely affect the long-term success and function of the transplanted organ.
Rejection happens when the recipient's immune system recognizes the donor kidney as foreign, prompting an immune response that damages the graft. There are two main types of rejection: Acute, which usually occurs within the first-year after transplantation, and chronic, which develops gradually over several years and is more prevalent. Chronic rejection is often associated with insufficient immunosuppression or non-compliance with medication regimens, leading to ongoing immune attacks that result in scarring and eventual loss of kidney function.
Around 15-20% of transplant recipients experience some form of rejection, highlighting the importance of regular monitoring and strict adherence to immunosuppressive therapy to reduce this risk. The treatment landscape for kidney transplant rejection has evolved significantly, with an emphasis on personalized immunosuppressive therapies to address both acute and chronic rejection episodes. Acute rejection, which can be TCMR or AMR, typically necessitates prompt intervention with escalated doses of immunosuppressants.
TCMR may require intravenous steroids or T-cell-depleting agents, while AMR may involve plasmapheresis or intravenous immunoglobulins. Early detection through regular monitoring and kidney biopsies is essential, as timely intervention can often reverse acute rejection and preserve graft function. A diverse array of approved medications is utilized to manage kidney transplant rejection, each with unique mechanisms of action aimed at ensuring long-term graft success.
Key treatments such as ENVARSUS XR, IDEFIRIX, NULOJIX, THYMOGLOBULIN, MYHIBBIN, and SIMULECT are instrumental in regulating immune responses and minimizing rejection risks. The development pipeline for prophylaxis kidney transplantation rejection features promising candidates, including MDR-101, tegoprubart (AT-1501), riliprubart (BIVV020, SAR445088), TRK-001 (Treg), TX200, and VEL-101, among others, also showing potential clinical trials focused on specific mechanisms within well-defined patient subgroups are expected to refine therapeutic strategies and identify the most effective interventions. Additionally, the identification of biomarkers and molecular targets associated with immune activation and graft injury holds significant promise for enhancing the understanding of kidney transplant rejection and developing novel therapeutic strategies to mitigate its complex immunopathology.
Scope of the Report Kidney transplant rejection report insights Kidney transplant rejection report key strengths Kidney transplant rejection report assessment For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. MENAFN07042025004107003653ID1109397739 Legal Disclaimer: MENAFN provides the information “as is” without warranty of any kind.
We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above..
